BTIG Research Reiterates Buy Rating for Sensei Biotherapeutics (NASDAQ:FTH)

Sensei Biotherapeutics (NASDAQ:FTH)‘s stock had its “buy” rating restated by stock analysts at BTIG Research in a report released on Thursday,Benzinga reports. They presently have a $55.00 price target on the stock. BTIG Research’s price objective suggests a potential upside of 112.60% from the stock’s current price.

A number of other equities analysts have also weighed in on the company. Wall Street Zen lowered Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Zacks Research raised Sensei Biotherapeutics to a “hold” rating in a report on Tuesday, April 21st. Leerink Partners assumed coverage on shares of Sensei Biotherapeutics in a research report on Monday, April 20th. They issued an “outperform” rating and a $50.00 price objective on the stock. Weiss Ratings assumed coverage on shares of Sensei Biotherapeutics in a research note on Wednesday, June 17th. They issued a “sell (d-)” rating on the stock. Finally, Robert W. Baird initiated coverage on shares of Sensei Biotherapeutics in a research note on Friday, June 26th. They issued an “outperform” rating and a $57.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $54.50.

Sensei Biotherapeutics Stock Down 0.3%

FTH opened at $25.87 on Thursday. The firm has a market cap of $34.67 million, a PE ratio of -0.18 and a beta of -0.26. Sensei Biotherapeutics has a one year low of $6.32 and a one year high of $37.90.

Sensei Biotherapeutics (NASDAQ:FTH) last issued its quarterly earnings data on Friday, May 15th. The company reported ($131.45) earnings per share (EPS) for the quarter. Sell-side analysts forecast that Sensei Biotherapeutics will post -16.61 EPS for the current fiscal year.

Insider Activity

In other news, CFO Brian C. Stephenson acquired 9,391 shares of the firm’s stock in a transaction that occurred on Wednesday, June 24th. The shares were bought at an average cost of $26.13 per share, with a total value of $245,386.83. Following the acquisition, the chief financial officer owned 26,804 shares in the company, valued at approximately $700,388.52. This represents a 53.93% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Anand Kiran Parikh bought 2,806 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average price of $19.76 per share, with a total value of $55,446.56. Following the transaction, the chief executive officer directly owned 764,234 shares in the company, valued at $15,101,263.84. The trade was a 0.37% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have bought 49,494 shares of company stock worth $1,188,822. 7.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Sensei Biotherapeutics

Hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC boosted its stake in shares of Sensei Biotherapeutics by 10.6% in the 4th quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock valued at $123,000 after purchasing an additional 1,100 shares in the last quarter. Bank of America Corp DE raised its position in Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after purchasing an additional 32,719 shares during the period. Stempoint Capital LP bought a new stake in Sensei Biotherapeutics in the first quarter worth $4,188,000. Finally, Vivo Capital LLC bought a new stake in Sensei Biotherapeutics in the first quarter worth $22,758,000. 10.50% of the stock is currently owned by institutional investors.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.